BCBS Michigan – Basic Benefit and Medical Policy – Noninvasive Techniques for Patients with Chronic Liver Disease

The policy has been updated to cover procedure codes *0002M and *0003M when criteria are met, effective Sept. 1, 2022.

The use of FibroSURE™ multianalyte assays (HCV FibroSURE, ASH FibroSURE, NASH FibroSURE) in chronic liver disease has been established. It may be considered a useful diagnostic option when indicated

Source: https://www.bcbsm.com/content/dam/microsites/corpcomm/provider/the_record/2023/jan/Record_0123w.shtml